138982-67-9
138982-67-9 structure
- Name: Ziprasidone Hydrochloride Monohydrate
- Chemical Name: ziprasidone hydrochloride hydrate
- CAS Number: 138982-67-9
- Molecular Formula: C21H24Cl2N4O2S
- Molecular Weight: 467.412
- Catalog: API Nervous system medication Antipsychotic
- Create Date: 2018-03-17 08:00:00
- Modify Date: 2026-06-30 12:12:49
-
Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.Target: 5-HT receptor; Dopamine receptorZiprasidone (hydrochloride) is the salt form of ziprasidone, which possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3].Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; SchizophreniaFDA Approved Date: February 2001
| Name | ziprasidone hydrochloride hydrate |
|---|---|
| Synonyms |
Ziprasidone for system suitability 2
Ziprasidone for system suitability 1 5-(2-(4-(1,2-Benzisothiazol-3-yl)Piperazin-1-yl)Ethyl)-6-Chloroindolin-2-One Hydrochloride Hydrate 5-(2-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one hydrochloride hydrate Ziprasidone HCl monohydrate - Bio-X 5-[2-[4-(1,2-benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride 88059, Geodon, 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one monohydrate hydrochloride Ziprasidone Hydrochloride Mohydrate Ziprasidone HCl hydrate 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-Indol-2-one hydrochloride hydrate (1:1:1) 5-(2-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one hydrochloride hyd 5-(2-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one hydrochloride hydrat 5-[2-[4-(1,2-Benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, Hydrochloride Monohydrate, -88059-1 Ziprasidone hydrochloride Ziprasidong Hcl 2-Benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1 Ziprasidone Hydrochloride Monohydrate 1.0 mg/ml in Methanol (as anhydrous free base) ZIPRASIDONE HCL Ziprasidone hydrochloride monohydrate a novel and potent dopamine and serotonin (5-HT) rector antagonist Ziprasidone Hydrochloride Monohydrate Also see: G364400 Ziprasidone Hydrochloride Monohydrate DISCONTINUED Ziprasidone (hydrochloride monohydrate) 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-on Monohydrochloride Monohydrate 138-9 5-[2-[4-(1,2-Benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride Ziprasidone hydrochloride monohydrate CRS 5-[2-[4-(1 ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE ZIPRASIDONE INTERMEDIATE 5-(2-(4-(1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chlorooxindole Monohydrochloride Monohydrate Ziprasidone monohydrate hydrochloride 5-[2-[4-(1,2-Benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride 5-[2-[4-(1,2-BENZISOTHIAZOL-3YL)-1-PIPERAZINYL]ETHYL]-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE, HYDROCHLORIDE MONOHYDRATE ZIPRASIDONE HYDROCHLORIDE (NON-STERILE DRUG SUBSTANCE) 5-[2-[4-(1,2-Benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride //BP 5-[2-[4-(1，2-Benzisothiazol-3-y1)-1-piperazinyl]ethyl]-6-chlom-1，3-dihydro-2H-indol-2-one 88059-1 2H-Indol-2-one, -4-(1,2-benzisothiazol-3-yl)-1-piperazinylethyl-6-chloro-1,3-dihydro-, monohydrochloride, monohydrate 5-{2-[4-(1,2-Benzothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride hydrate Ziprasidone hydrochloride monohydrate (-88059) Geodon Hydrochloride Hydrate Ziprasidone Hydrochloride MFCD06795476 Ziprasidone Hydrochloride Monohydra cp 88059-1 3-dihydro-2H-indol-2-one hydrochloride Ziprasidone Ziprasidone (hydrochloride hydrate) 5-{2-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride hydrate ZIPRASITONE HCl MONOHYDRATE 5-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]-ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one HCl hydrate (1:1:1) 5-(2-(4-(1,2-Benzisothiazol-3-yl)Piperazin-1-yl)Ethyl) Ziprasidone hydrochloride solution ZIPRASIDONE HCL MONOHYDRATE Ziprasidone hydrochloride monohydrate, 10 mM in DMSO 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, hydrochloride, hydrate (1:1:1) |
| Description | Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.Target: 5-HT receptor; Dopamine receptorZiprasidone (hydrochloride) is the salt form of ziprasidone, which possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3].Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; SchizophreniaFDA Approved Date: February 2001 |
|---|---|
| Related Catalog | |
| References |
[5]. Ziprasidone |
| Boiling Point | 554.8ºC at 760 mmHg |
|---|---|
| Melting Point | 300°C |
| Molecular Formula | C21H24Cl2N4O2S |
| Molecular Weight | 467.412 |
| Exact Mass | 466.099701 |
| PSA | 85.94000 |
| LogP | 4.68760 |
| Vapour Pressure | 2.38E-12mmHg at 25°C |
| Storage condition | Room temp |
| Symbol |
GHS07, GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H317-H373 |
| Precautionary Statements | P260-P280 |
| Target Organs | Central nervous system, Liver |
| Hazard Codes | Xi |
| Risk Phrases | R36/37/38:Irritating to eyes, respiratory system and skin . |
| Safety Phrases | S24/25 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2934999090 |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |